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Prognostic factors, effectiveness and safety of 
endoscopic balloon dilatation for de novo and 
anastomotic strictures in Crohn’s disease—A 
multicenter “real life” study
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Abstract: Introduction: Crohn’s disease (CD) is a chronic inflammatory disease which 
is frequently complicated by obstructive symptoms secondary to development of 
intestinal strictures. The aim of this “real life” study was to assess the effectiveness, 
safety and outcome of endoscopic balloon dilatation (EBD) in de novo vs. anasto-
motic stenoses. Patients and methods: Data of 93 EBDs in 46 CD patients were retro-
spectively analyzed. Technical success rate was defined as the ability of endoscope 
to traverse the stenosis after dilatation. Long-term clinical success rate was claimed 
if a patient remained asymptomatic and did not require surgery or further endo-
scopic dilatation following the technical success. Results: About 62.4% of strictures 
were de novo and 37.6% anastomotic. The elapsed time between diagnosis and 
the first balloon dilatation was 9.5 (0–35) years. About 73.1% of dilatations were 
successful over a short-term period without serious complications. About 47.8% of 
patients showed that EBD is effective over a long-term period. EBD of anastomotic 
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surgical intervention. Treatment of these strictures 
in gut is surgical or endoscopic intervention. Our 
aim was to assess effectiveness and safety of 
endoscopic balloon dilatation (EBD) for de novo 
and anastomotic strictures in CD and to determine 
factors that affect on effectiveness and outcome 
of this endoscopic intervention. In this article EBD 
is an effective therapy of short strictures in CD 
with low complication rate. Using this endoscopic 
method we can avoid surgical interventions in 
most of the cases. According to our results, EBD 
of anastomotic stenosis may be more preferable 
than the de novo strictures.
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strictures showed better outcome than that of de novo strictures, however biologi-
cal therapy before or after dilatation, immunomodulatory therapy and the time 
between the diagnosis and the first dilatation had no influence on long-term ef-
fectiveness. Nine subjects required surgery due to strictures after balloon dilatation. 
Conclusion: The results of this study highlight that EBD is an effective therapy of 
short strictures in CD with low complication rate. Using this endoscopic method we 
can avoid surgical interventions in most of the cases. EBD of anastomotic stenosis 
may be more preferable than that of the de novo strictures.
Subjects: Chronic Diseases; Complementary & Alternative Medicine; Gastroenterology
Keywords: Crohn’s disease; balloon dilatation; stricture; endoscopy
1. Introduction
One of the major forms of inflammatory bowel diseases is Crohn’s disease (CD); this chronic disor-
der of the intestinal tract with transmural inflammation can occur anywhere from the mouth to the 
anus, but commonly affects the terminal ileum. The phenotype of CD has been categorized by 
Montreal classification considering the age at the time of diagnosis, the location and behaviour of 
the disease (Satsangi, Silverberg, Vermeire, & Colombel, 2006). Main categories of CD behaviour are 
“non-stricturing, non-penetrating”, “stricturing” and “penetrating” depending on the presence or 
absence of fistulas, abscesses and strictures. It seems that CD behaviour changes over the course 
of the disease: almost half of CD patients had changed in behaviour over 10 years, mainly from 
non-stricturing, non-penetrating disease to either stricturing or penetrating disease (Louis et al., 
2001). The stricturing form is not common at the diagnosis; however it becomes more frequent over 
time, which may be the consequence of chronic inflammation with cell death and consecutive scar-
ring (Brenmoehl, Falk, Göke, Schölmerich, & Rogler, 2008). Intestinal strictures may lead to such 
severe conditions as subileus and ileus, perforation or abscess formation. Despite the advances in 
the medical therapy of inflammatory bowel diseases, intervention is necessary in the majority of 
stricturing CD cases as showed by the data in the literature: up to 80% of patients require surgery 
within 10 years after the diagnosis and the cumulative rate of surgery after 10 years is 64% (Nanda 
et al., 2013; Wibmer, Kroesen, Gröne, Buhr, & Ritz, 2010). Endoscopic balloon dilatation (EBD) is a 
minimally invasive therapeutic alternative to surgery in stricturing CD. EBD in stricturing CD is gen-
erally performed in the colon and terminal ileum, however advanced techniques like single and 
double-balloon endoscopy facilitate the access to more oral regions of the small bowel. A technical 
success rate of 71–100% and a major complication rate of 0–18% have been reported with EBD 
(Wibmer et al., 2010).
The aim of our ‘real life’ study was to evaluate the short- and long-term efficacy and the safety of 
EBD in CD patients with de novo and anastomotic strictures.
2. Material and methods
2.1. Patients’ characteristics
Ninety-three EBDs were performed to treat 46 CD patients (23 males, 23 females, mean age at first 
EBD: 38 [18–67] years) in two tertiary centres in Hungary between November 2002 and March 2014. 
Based on the data from this study population, a retrospective analysis was performed. All patients 
had an established diagnosis of CD confirmed by clinical, endoscopic and histological criteria; in ad-
dition, disease location and behaviour were classified according to the Montreal classification 
(Silverberg et al., 2005). Inclusion criteria were clinical symptoms of intestinal obstruction, and ab-
sence of intestinal fistulas, abscesses, ulcers around the strictures or moderate/severe disease activ-
ity. All of our enrolled patients presented symptoms such as prolonged gastric emptying, abdominal 
pain, cramps, nausea and bloating, furthermore, all of them had de novo or anastomotic strictures 
through which the endoscope could not pass.
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Prior to the EBD 22 subjects had undergone surgical bowel resections. About 35 out of 93 dilata-
tions were performed due to stricture of intestinal anastomosis.
2.2. Dilatation protocol
All patients had given their written informed consent to the procedure. The endoscopic procedure 
was chosen on the basis of the location of the stricture. Gastric or duodenal strictures were assessed 
by gastroscopy. EBD for colonic or ileocolonic strictures was performed by colonoscopy. Conscious 
sedation was used if the subject requested it. EBD was performed by experienced endoscopists in 
accordance with protocols. Appropriate laboratory tests were completed before the intervention. 
Olympus CF-Q165I colonoscopes and Olympus GIF-Q165 or Olympus GIF-2T160 gastroscopes were 
used for EBD. Dilatations were carried out using through-the-scope balloons (CRETM Wire-guided oe-
sophageal/colonic Balloon Dilatation Catheter, Boston Scientific, USA) with diameters from 10 to 
18 mm. The balloon was led into the stricture under visual control. After having reached the correct 
position of the balloon, it was insufflated with air (under 2 atmospheric pressure) for 2–3 min; this 
procedure was repeated for several times until the endoscope could pass through the stenosis – 3 
attempts were made on average. Technical/short-term failure was obtained if the balloon did not 
reach the correct position or if despite the multistep inflation, the diameter of bowel did not change 
significantly.
To inquire any EBD-related complications, patients were observed in our hospital overnight.
2.3. Definitions
Short-term (technical) success was defined as the ability of the routinely used 12 mm diameter sized 
endoscope to pass the stenosis after dilatation.
Long-term clinical success (outcome) was claimed if a patient remained asymptomatic and did 
not require surgery or further endoscopic dilatation, following technical success.
2.4. Statistical analysis
Categorical variables are presented as counts (percentages), continuous variables are presented in 
mean (range) format. The collected data were analyzed using χ2 test, Fisher’s exact test and logistic 
regression analysis. For multiple comparisons ANOVA was carried out and followed by Bonferroni 
post hoc tests. Pairwise comparisons were performed on estimated marginal means by considering 
the presence or absence of interaction. p < 0.05 was considered as statistically significant. The sur-
gery-free survival curve was constructed with the nonparametric Kaplan-Meier estimator with ac-
companying 95% confidence interval. Dividing simply the number of patients undergoing surgery (9) 
by the total number of patients (46), i.e. calculating simply a frequency is not the sound way to cal-
culate the risk of surgery as we are dealing with data involving the follow-up of patients. The prob-
lem with this logic is that it assumes that all patients contribute 1/46, but this is not correct in this 
setting: after the first patient underwent surgery, the at-risk population consists only of 45 patients, 
thus the second patient contributes 1/45 and so on. This is just the central logic of Kaplan-Meier 
survival analysis, where the at-risk population is always reduced whenever an end point (or censor-
ing) happens. Our calculation is consistent with the statistical practice in this field (Wibmer et al., 
2010). The statistical analysis was performed using R statistical software (version 3.1.0).
3. Results
3.1. Patients and strictures characteristics
Overall, 93 EBDs were performed on 50 strictures in 46 subjects. Patients and disease characteristics 
are shown in Table 1. The mean duration of CD was 9.5 years. The mean age of the patients was 25 
(8–59) years at the time of diagnosis of CD. Colonic and ileocolonic location and stricturing behaviour 
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at diagnosis were the most frequent phenotypes of CD (Table 1.). However, some patients changed 
in disease behaviour over the time; in our cohort there were 11 subjects with non-stricturing, non-
penetrating and 8 subjects with penetrating disease behaviour at the diagnosis of CD. A great pro-
portion (84.9%) of dilatation was performed in the lower gastrointestinal tract (79 of 93). The mean 
time between the diagnosis and the development of strictures with symptoms was 7.3 (0–27) years. 
The time between the diagnosis of CD and the first balloon dilatation was 9.5 (0–35) years, therefore 
the elapsed time between stenotizing symptoms and EBD was 2.98 (0–17) years. The mean time 
between bowel resection and the first EBD was 82 (14–228) months in patients with anastomotic 
strictures (Figure 1). Fifty-eight (62.4%) EBDs were performed on de novo strictures and 35 (37.6%) 
on anastomotic ones. None of the strictures length was beyond used balloon length (5.5 cm). In de 
novo group the elapsed time between first stricturing sypmtoms and EBD was 2 (0–9) years, while in 
the anastomotic group it was 4 (0–17) years. Forty patients were on medical therapy at the time of 
Figure 1. Patients and strictures 
characteristics.
Notes: The mean time 
between the diagnosis and 
the development of strictures 
with symptoms was 7.04 
and 7.6 years in de novo 
and anastomotic strictures, 
respectively. The elapsed time 
between the diagnosis and the 
first balloon dilatation was 8.7 
and 10.4 years, respectively. 
The mean time between 
diagnosis and colon resection 
was 4 years in patients with 
anastomotic strictures. The 
mean time between bowel 
resection and the first EBD 
was 6.83 years in patients with 
anastomotic strictures.
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Figure 2. Likelihood of surgery 
free survival among our 
patients.
Notes: Overall, 9 out of 46 
dilated subjects underwent 
surgery during the follow-up 
period. The mean surgery free 
survival time was 78 months 
(95% CI: 59–98 months). The 
Kaplan–Meier curve shows that 
at month 12 approximately 
90% of patients, at month 24 
approximately 80% of patients 
was surgery free; however after 
50 months the surgery free 
rate was 60.7%.
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the first EBD: 22 patients received 5-aminosalicylic, 16 azathioprine and 12 corticosteroid therapy. 
Eight patients were on anti-TNF therapy at the time of the first EBD; although 21 patients received 
anti-TNF agent before the first EBD. After the first EBD, anti-TNF therapy was started in 24 cases. Only 
five patients were smokers.
Table 1. Clinical data of enrolled patients
No.
Enrolled patients 46
Gender (male/female) 23/23
Disease localisation at diagnosis
 L1 7
 L2 16
 L3 15
 L4 2
 L1 + L4 3
 L2 + L4 3
Disease behaviour at diagnosis
 B1 11
 B2 20
 B3 8
 B2 + B3 3
 Data missing 4
Smoking status
 No 19
 Yes 5
 Stopped 11
 Data missing 11
Disease duration at first EBD (years) 9.5 (0–35)
Age at first EBD (mean [min–max] years) 34.2 (13–67)
Time between diagnosis and development of stricture simptoms (mean [min–max] years) 7.3 (0–27)
Medical therapy at the time of first EBD
 No treatment 5
 5-ASA 22
 Azathioprine 16
 Corticosteroids 12
 Anti-TNF-α 8
 Metothrexate 2
 Topical steroid 2
 Antibiotics 10
 Proton-pump inhibitors 11
No. of strictures 50
No. of dilatations 93
 De novo 58
 Anastomotic 35
Surgery after EBD 9
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3.2. Short-term outcome/technical success
Technical success was achieved in 73.1% of the dilatations. According to the number of cases, tech-
nical success rate of the first EBD was 73.9%. In Fisher’s exact test, the type of stricture (de novo vs. 
anastomotic) did not have an influence on the short-term efficacy of EBD (p = 0.999). Dilatations 
were performed without serious complications.
3.3. Long-term outcome
The median follow-up of the patients was 26 (1–109) months. Twenty-two subjects sustained re-
sponse to a single dilatation, with avoidance of further EBD or surgical interventions during the fol-
low-up time. Thus, EBD showed long-term success in 47.8% of our patients. However, re-strictures 
occurred in 20 subjects during the observation period. Re-dilatation was performed in all patients 
with re-strictures: seven patients had two dilatations, 8 patients had three dilatations and 5 patients 
had more than three dilatations. The average number of EBD was 3.3 in this subgroup of patients. 
The mean time between the first and the second EBD was 11.1 (0–40) months, it was 10.9 (0–42) 
months between the second and the third, and 16.6 (5–51) months between the third and the fourth 
dilatation. The mean time between dilatations was 9.96 (1–16.6) months. The elapsed time between 
the diagnosis and the first balloon dilatation, the mean time between the diagnosis and the develop-
ment of strictures with symptoms, gender, age and smoking status had no influence on long-term 
clinical success (p = 0.714, p = 0.942, p = 0.751, p = 0.685, p = 0.322). No association was found be-
tween disease location and the number of EBD/subject (p = 0.39), behaviour and number of EBD/
subject (p = 0.21). Anti-TNF therapy before and after EBD did not have an influence on long-term 
success (p = 0.99 and p = 0.99, respectively), nor on the number of dilatations (p = 0.11). Overall, 19 
subjects were on immunomodulatory therapy at the time of the first EBD. In logistic regression, 
medication (immunosuppressants, anti-TNF, both or none of them) were not associated with long-
term success in our study (p = 0.29). Depending on the type of the stricture, an interesting difference 
was found regarding the outcome: long-term success rate was 29.2% in the de novo group and 
68.2% in the anastomotic group (p = 0.02). Less patients needed surgery in the anastomotic group 
(de novo group: 20.8% vs. anastomotic group: 9.1%; p = 0.07); however, the number of dilatations did 
not depend on the stricture type (mean number of dilatations was 2.3 in de novo vs. 1.7 in anasto-
motic group; p = 0.2). Overall, 9 out of 46 dilated subjects underwent surgery as the subsequent 
therapeutic option indicated by strictures. Cumulative recurrence estimates from survival analyses 
were used to determine surgery free survival. According to our data, the mean surgery free survival 
time was 78 months (95% CI: 59–98 months). In the first year 90% of patients, and in second year 
80% of them managed to avoid surgical procedures, however after 50 months the surgery free rate 
was only 60.7% (Figure 2). Surgery free survival rate did not differ significantly between de novo and 
Figure 3. Likelihood of surgery 
free survival among patients 
with de novo and anastomotic 
strictures.
Notes: Less patients needed 
surgery in the anastomotic 
group. The Kaplan-Meier 
curve shows that at month 12 
approximately 80% of patients 
with de novo and 100% of 
patients with anastomotic 
strictures was surgery free.
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anastomotic group (0.099 by log rank test); however, statistical comparison of groups is limited, 
because of small number of subject who underwent surgery (Figure 3).
3.4. Safety
Dilatations were performed without perforations or other significant complications such as gastro-
intestinal bleeding with need for blood transfusion or abdominal pain requiring hospitalization; how-
ever, a minority of subjects developed slight bleeding in the area of the dilatation, which resolved 
spontaneously.
4. Discussion
The outcomes of medical treatment of stricturing CD are poor due to the reduced ability to control 
the progress of fibrosis (Samimi, Flasar, Kavic, Tracy, & Cross, 2010), and the risk of recurrence after 
intestinal resection is high, thus the management of de novo and postoperative intestinal strictures 
is a relevant issue (Greenstein, Sachar, Pasternack, & Janowitz, 1975; Rutgeerts et al., 1990).
In recent years EBD has become a relatively easy and quick to perform procedure for managing 
intestinal strictures with high success rate. It offers some advantages as being minimally invasive, it 
saves the intestinal length avoiding short-bowel syndrome, and avoids risks associated with general 
anaesthesia.
As stated in our research, several other studies also reported that EBD can be a safe alternative to 
surgical resection or stricturoplasty (Couckuyt, Gevers, Coremans, Hiele, & Rutgeerts, 1995; Ferlitsch 
et al., 2006; Karstensen, Hendel, & Vilmann, 2012; Mueller, Rieder, Bechtner, & Pfeiffer, 2010). There 
were no fatal complications in the reported studies. Major complication rates in a review ranged 
from 0 to 18% with a median of 3% (Karstensen et al., 2012). As a matter of fact, in literature, higher 
complication rates were observed using larger balloon diameters and more frequent dilatations 
(Couckuyt et al., 1995; Gustavsson et al., 2012). Balloons with a diameter of 10–18 mm were used 
depending on the stricture, and they were insufflated by a multistep inflation with air [2 ATM pres-
sure that is slightly smaller than the one in manufacturer’s instruction (3.4–10 ATM)] and this step-
wise technique seems to be safe and effective. One of the limitations of this procedure is the length 
of the stricture, as reported that the main field of application is up to 5 cm of length (short strictures) 
(Hassan et al., 2007; Mueller et al., 2010). Technical success was 73.1% in our cohort; that is in ac-
cordance with the results of other studies (71–100%) (Scimeca et al., 2011; Wibmer et al., 2010). 
However, 44.4% of our patients had more than one dilatation, which showed that EBD could be 
safely repeated and may obtain a symptomatic relief after further dilatations. Long-term success 
was 47.8% in our study, therefore almost half of the patients remained asymptomatic after the first 
dilatation; however, repeated EBDs led most of the remaining patients to be asymptomatic resulting 
in a surgery-free outcome during the follow-up period. In this study the post EBD surgical rate 
(39.3%) was slightly higher, compared to others with the mean of 28.5% (Wibmer et al., 2010). The 
long-term success rate after a single dilatation varies between 21 and 51% in the literature (Honzawa 
et al., 2013; Nanda et al., 2013; Scimeca et al., 2011). A meta-analysis by Hassan et al. (2007) showed 
a short-term success rate of overall 86% with complication rates of 0–11%, and the long-term effi-
cacy was 58%. Some studies suggest an association between technical success and long-term out-
come: technical success predicts a lower rate of surgery (Scimeca et al., 2011). Hassan’s review 
showed that 89% of those subjects for whom EBD was not successful technically, surgical interven-
tion were needed. In our study, 4 out of 9 patients (44.4%) who underwent a surgical procedure had 
technically failed EBD. Long-term data on the outcomes and parameters predictive of success are 
not obvious, and the influencing factors are largely unclear. As mentioned above, technical success 
and short strictures(Couckuyt et al., 1995; Scimeca et al., 2011) as well as absence of ulcers in the 
stricture were found to be beneficial prognostic factors of outcome (Endo et al., 2013). Recurrence of 
postoperative CD stricture is common, as the study population showed: more than one third of pa-
tients had anastomotic strictures. As theoretically expected, a significantly favourable long-term 
outcome was observed in the anastomotic group in our study. Shorter length and less severe mu-
cosal and transmural inflammation may explain the higher success rate. There is no clear evidence 
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about the therapy after dilatation. Some authors suggest the efficacy of certain agents like the 
combination of budesonide and azathioprine (Raedler, Peters, & Schreiber, 1997), but others did not 
prove it (Nanda et al., 2013; Ono et al., 2012; Thienpont et al., 2010; Thomas-Gibson et al., 2003). 
Views regarding the influence of anti-TNF agents on strictures have been conflicting (Nakazato, Oku, 
Yamane, Tsuruta, & Suzuki, 2002; Theiss, Simmons, Jobin, & Lund, 2005; Vassallo, Matteson, & 
Thomas, 2002). We did not confirm any association between EBD and medication of CD; neither the 
use of anti-TNF before or after EBD, nor immunosuppressants were predictive factors for long-term 
outcome of EBD. In addition, anti-TNF therapy did not show association with the number of dilata-
tions. Analysis of data from 25 patients by Honzawa et al. (2013) showed significant difference in the 
mean number of dilation procedures per patient between the early immunmodulatory drug induc-
tion and post-immunmodulatory drug-induction groups, although no significant difference in the 
cumulative non-surgical rate was observed between the two groups. A study from Belgium also 
confirms that none of the therapies were associated with an increased risk of surgical relapse 
(Thienpont et al., 2010). An outstanding question is the timing of the procedure, whether the elapsed 
time between the diagnosis and the first EBD or the one between the development of strictures and 
the first EBD has an influence on effectiveness. Our results highlight that the above mentioned fac-
tors did not predict the successfulness of EBD, thus despite the elapsed time it could be performed 
with a good chance in every eligible patients.
The main limitation of our study is small number of subject, however sufficient number of dilata-
tions enabled to performe conclusive statistical analysis. Results showed clearly that EBD is an effec-
tive tool to avoid surgical interventions in most of the cases, and its use may be more preferable in 
case of anastomotic stenoses than the de novo strictures. Another limitation was that CT or MRi ex-
amination wasn’t done in every case, thus length of strictures was estimated only by endoscope. We 
used through-the-scope balloons with diameters from 10 to 18 mm and length of 5.5 cm. None of 
the strictures was beyond used balloon length (5.5 cm).
In summary, our results showed high technical success rate with a decreased need of surgery dur-
ing the follow-up period. However, in 20 of 46 cases, multiple dilatations were needed to avoid surgi-
cal intervention. On the other hand, these multiple interventions did not impair the good safety 
profile of EBD resulting in a 60.7% surgery-free rate during the more than 3 years follow-up period 
(Figure 4). A study from Japan showed that EBD for small bowel strictures secondary to CD provides 
success for short and long-term efficacy as well; however, the high re-dilatation rate is one of the 
clinical problems of this procedure (Hirai et al., 2014). We did not find predictive factors for long-term 
success except the type of stenosis, as the immunosuppressive status of patients, medication, dis-
ease duration, and elapsed time between EBD and the development of strictures did not influence 
the efficacy of EBD. Thus, in the light of these findings, EBD is an effective therapy of short strictures 
in CD with low complication rate mainly in case of postsurgical anastomotic Ruttgeert’s score of 4 
points recurrence (Sostegni et al., 2003). Our recommendation is the use of pneumatic balloons 
Figure 4. Overall efficacy of 
EBD: 73.9% of patients showed 
technical success at the first 
EBD and 47.8% of patients 
showed that endoscopic 
balloon dilatation is effective 
over a long-term period i.e. 
at the end of the median 26 
(range, 1–109) months follow-
up period.
Note: Nevertheless, at the end 
of follow-up period the surgery 
free rate was 60.7%.
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insufflated by a multistep inflation due to its excellent safety profile. Fibrotic complications remained 
the vague field of CD, thus there is a need for further research to improve therapy and reduce hospi-
talization rates; however, by using this endoscopic method we can avoid surgical interventions in 
most of the cases.
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